cell-lung

TECENTRIQ + CARBOPLATIN/ETOPOSIDE

A proven connection in 1L SCLC

TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small-cell lung cancer
(ES-SCLC).1

Setting the standard of care in SCLC

TECENTRIQ was the first treatment advance in SCLC in over 20 years, showing a significant survival benefit in a hard-to-treat patient population.2

IMpower133: A Phase 3 efficacy trial in first-line ES-SCLC2 

A Phase 3 study in patients (n=403) with extensive-stage SCLC randomised to receive induction therapy with carboplatin and etoposide in combination with TECENTRIQ or placebo, and then TECENTRIQ or placebo maintenance therapy until disease progression or unacceptable toxicity. Primary endpoints included OS and PFS.2

impower133

Carbo/etop; carboplatin/etoposide.

*The 1- and 2-year overall survival (OS) rates were pre-specified secondary endpoints in IMpower133 (n=201 for the Tecentriq + CP/ET arm and n=202 for control arm), 2,4,5 the median follow-up was 35.7 months for the experimental arm and 26.4 months for the control arm (CCOD: 24 Sept 2022). †The 3-, 4-, and 5-year OS rates from the exploratory merged analysis of IMpower133 and IMbrella A extension (n=18 patients who rolled over from the Tecentriq + CP/ET arm of IMpower133) were not pre-specified and are considered exploratory; the median follow-up was 59.4 months (CCOD: 16 March 2023).6

 

CCOD=clinical cutoff date

Carbo/etop, carboplatin/etoposide.

Carbo/etop; carboplatin/etoposide.

Carbo/etop; carboplatin/etoposide.
†As of data cut-off date 24th January 2019, median follow-up: 22.9 months.

TECENTRIQ: First major treatment advance for first-line ES-SCLC in over 20 years7,8

See how TECENTRIQ can help patients with lung cancer

  1. TECENTRIQ (atezolizumab), Summary of Product Characteristics. 03 August 2023.
  2. Horn L, et al. N Engl J Med 2018; 379:2220-2229.
  3. Liu et al. IMpower 133LTS, ESMO 2020.
  4. Liu SV, et al. J Clin Oncol 2021;39:619-30.
  5. Liu SV, et al. Presented at ESMO Virtual Congress. 19-21 September 2020.
  6. Liu et al. Presented at World Conference on Lung Cancer; 9–12 September 2023.
  7. Sabari JK, Lok BH, Laird JH, et al. Nat Rev Clin Oncol 2017;14:549-561.
  8. Armstrong SA, Liu SV. Immune checkpoint in small cell lung cancer: a partially realized potential. Adv Ther 2019,36:1826-1832.